La combinación de T-DXd con Sotorasib mostró una eficacia prometedora en estudios preclínicos de cáncer de pulmón de células no pequeñas con mutación KRAS G12C – Oncodaily
La combinación de T-DXd con Sotorasib demostró una eficacia prometedora en estudios preclínicos de cáncer de pulmón de células no pequeñas con mutación KRAS G12C.
Contenido completo del articulo
T-DXd Plus Sotorasib in KRAS G12C-Mutant NSCLC showed durable preclinical tumor regressions and highlighted HER2 testing gaps. , ADCs, Antibody drug conjugates, HER2, HER2 expression, HER2 IHC, KRAS G12C, KRAS G12C-mutant NSCLC, KRAS inhibitor resistance, Lung cancer, NSCLC, OncoDaily Lung, Precision Oncology, preclinical oncology, Sotorasib, T-Dxd, targeted therapy, Thoracic Oncology, Trastuzumab deruxtecan, xenograft models
المنتجات المرتبطة بهذا المقال
تمت مطابقة هذه المنتجات تلقائيا استنادا الى عنوان المقال وملخصه ومحتواه.
الاسئلة الشائعة
Which products are related to this article?
The system matched these relevant products from the article content: لوسيوس سوتوراسيب – اشترِ عبر الإنترنت سوتولدكس سوتوراسيب 120 ملغ.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.